Last updated: 11/07/2018 15:11:36

study to evaluate GlaxoSmithKline (GSK) Biologicals’ MenC-TT vaccine and Hib-MenC-TT vaccine in infants

Request patient level data
GSK study ID
711202/001
See study documents
Clinicaltrials.gov ID
NCT00135486
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Completed
Completed
Overview
Eligibility
Locations
Study documents
Results summary
Plain language summaries
Additional information

Trial overview

Official title: Evaluate immunogenicity, reactogenicity, safety of GSK Biologicals’ MenC-TT vaccine (2 formulations) given with Infanrix hexa® + GSK Biologicals’ Hib MenC-TT vaccine (2 formulations) given with Infanrix penta® to infants in mths 3,4,5 of life
Trial description: The purpose of this primary vaccination study is to evaluate the immunogenicity, safety and reactogenicity of three doses of GSK Biologicals' MenC-TT (Neisseria meningitidis group C polysaccharide-tetanus toxoid) vaccine (2 different formulations) and of three doses of GSK Biologicals' Hib-MenC-TT (Haemophilus influenzae type b-MenC-TT) vaccine (2 different formulations) when given to infants in their 3rd, 4th, and 5th months of life. Concomitant vaccines were given to all children to complete the vaccination agenda.
Primary purpose:
Prevention
Trial design:
Parallel Assignment
Masking:
None (Open Label)
Allocation:
Randomized
Primary outcomes:

Evaluation of Meningococcal C serum bactericidal assay using rabbit complement (rSBA-MenC) antibody titers ≥ 1:8 & ≥ 1:128 and titers

Timeframe: Prior to vaccination, one month after the 2nd and 3rd vaccine doses

Evaluation of anti-polysaccharide C (anti-PSC) antibody concentrations ≥ 0.3 µg/mL & ≥ 2 µg/mL and concentrations

Timeframe: Prior to vaccination, one month after the 2nd and 3rd vaccine doses

Evaluation of anti-polyribosyl ribitol phosphate (anti-PRP) antibody concentrations ≥ 0.15 µg/mL & ≥ 1 µg/mL and concentrations

Timeframe: Prior to vaccination, one month after the 2nd and 3rd vaccine doses

Evaluation of anti-diphtheria antibody concentrations ≥ 0.1 IU/mL by ELISA

Timeframe: Prior to and one month after the 3rd vaccine dose

Evaluation of anti-tetanus antibody concentrations ≥ 0.1 IU/mL

Timeframe: Prior to and one month after the 3rd vaccine dose

Evaluation of anti-hepatitis B surface antigen (anti-HBs) antibody concentrations ≥ 10 mIU/mL

Timeframe: Prior to and one month after the 3rd vaccine dose

Evaluation of anti-poliovirus types 1, 2 and 3 antibody titers ≥ 8 mIU/mL

Timeframe: Prior to and one month after the 3rd vaccine dose

Vaccine response to pertussis toxoid (PT)

Timeframe: Prior to 3rd vaccine dose

Evaluation of anti-diphtheria antibody concentrations

Timeframe: Prior to 3rd vaccine dose

Anti-poliovirus types 1, 2 and 3 antibody titers

Timeframe: Prior to and one month after the 3rd vaccine dose

Occurrence of solicited local injection site symptoms

Timeframe: During the solicited follow-up period (Day 0 7) following administration of each vaccine dose

Occurrence of solicited systemic symptoms

Timeframe: During the solicited follow-up period (Day 0 7) following administration of each vaccine dose

Occurrence of unsolicited non-serious adverse events (AEs)

Timeframe: Within one month (Day 0 30) after each vaccination

Occurrence of any serious adverse events (SAEs)

Timeframe: Throughout the entire study period up to and including one month (maximum 30 days) after the last vaccine dose

Vaccine response to pertussis toxoid (PT)

Timeframe: One month after the 3rd vaccine dose

Vaccine response to filamentous haemagglutinin (FHA)

Timeframe: Prior to 3rd vaccine dose

Vaccine response to filamentous haemagglutinin (FHA)

Timeframe: One month after the 3rd vaccine dose

Vaccine response to pertactin (PRN)

Timeframe: Prior to 3rd vaccine dose

Vaccine response to pertactin (PRN)

Timeframe: One month after the 3rd vaccine dose

Evaluation of anti-diphtheria antibody concentrations

Timeframe: One month after the 3rd vaccine dose

Evaluation of anti-tetanus antibody concentrations

Timeframe: Prior to 3rd vaccine dose

Evaluation of anti-tetanus antibody concentrations

Timeframe: One month after the 3rd vaccine dose

Evaluation of anti-HBs antibody concentrations

Timeframe: Prior to 3rd vaccine dose

Evaluation of anti-HBs antibody concentrations

Timeframe: One month after the 3rd vaccine dose

Evaluation of anti-PT antibody concentrations

Timeframe: Prior to 3rd vaccine dose

Evaluation of anti-PT antibody concentrations

Timeframe: One month after the 3rd vaccine dose

Evaluation of anti-FHA antibody concentrations

Timeframe: Prior to 3rd vaccine dose

Evaluation of anti-FHA antibody concentrations

Timeframe: One month after the 3rd vaccine dose

Evaluation of anti-PRN antibody concentrations

Timeframe: Prior to 3rd vaccine dose

Evaluation of anti-PRN antibody concentrations

Timeframe: One month after the 3rd vaccine dose

Secondary outcomes:
Not applicable
Interventions:
Biological/vaccine: MenC-TT
Biological/vaccine: Hib-MenC-TT
Enrollment:
500
Observational study model:
Not applicable
Primary completion date:
2003-31-01
Time perspective:
Not applicable
Clinical publications:
Schmitt HJ et al. (2007) Immunogenicity, reactogenicity, and immune memory after primary vaccination with a novel Haemophilus influenzae-Neisseria meningitidis serogroup C conjugate vaccine. Clin Vaccine Immunol. 14(4):426–434.
Medical condition
Infections, Meningococcal
Product
Meningococcal Vaccine
Collaborators
Not applicable
Study date(s)
March 2002 to January 2003
Type
Interventional
Phase
2

Participation criteria

Sex
Female & Male
Age
8 - 16 weeks
Accepts healthy volunteers
Yes
  • Healthy male or female infants, 8 to 16 weeks of age at the time of the first vaccination.
  • Previous vaccination against OR history of OR exposure since birth to diphtheria, pertussis, tetanus, polio, hepatitis B, Hib and/or meningococcal disease.
  • Planned administration/administration of a vaccine not foreseen in the study since birth.
Inclusion and exclusion criteria
Inclusion criteria:
  • Healthy male or female infants, 8 to 16 weeks of age at the time of the first vaccination.
Exclusion criteria:
  • Previous vaccination against OR history of OR exposure since birth to diphtheria, pertussis, tetanus, polio, hepatitis B, Hib and/or meningococcal disease.
  • Planned administration/administration of a vaccine not foreseen in the study since birth.
  • Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection.
  • A family history of congenital or hereditary immunodeficiency.
  • History of any neurologic disorders or seizures, allergic disease or reactions likely to be exacerbated by any component of the vaccine

Trial location(s)

No location data available.

Study documents

Clinical study report
Available language(s): English
Download document(s)
Scientific result summary
Available language(s): English
Download document(s)

If you wish to request for full study report, please contact - [email protected]

Results overview

Refer to study documents

Recruitment status
Completed
Actual primary completion date
2003-31-01
Actual study completion date
2003-31-01

Plain language summaries

Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.

Additional information about the trial

Participate in clinical trial
Additional information
Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.
Click here
Access to clinical trial data by researchers
Visit website